168 related articles for article (PubMed ID: 3331653)
21. [Thymic hormone treatment of acute and chronic respiratory infections in the elderly].
Agostinelli M; Zaia AM; Fiorentini A; Stecconi R; Fabris N; Scalise G
Recenti Prog Med; 1989; 80(7-8):438-41. PubMed ID: 2682857
[TBL] [Abstract][Full Text] [Related]
22. The effect of thymopentin treatment on the relapse rate in frequently relapsing herpes simplex virus infections.
Haneke E; Bolla K; Degreef H; Djawari D; Demaubeuge J; Molin L; Panconesi E; Schöpf E; Stengel R; Stingl G
Int J Clin Pharmacol Res; 1984; 4(6):439-43. PubMed ID: 6085327
[TBL] [Abstract][Full Text] [Related]
23. A case of Di George syndrome treated with thymopoietin pentapeptide (TP-5) demonstrating an adherent suppressor cell of lymphocyte function.
Joffe MI; Sochett E; Pettifor JM; Rabson AR
J Clin Lab Immunol; 1982 May; 8(1):69-73. PubMed ID: 6212686
[TBL] [Abstract][Full Text] [Related]
24. [Immunologic and cytologic aspects of Hashimoto's thyroiditis during therapy with thymopentin].
Aiello A; Cristofaro M; Carrozza F; Di Rienzo G; Carile L
Clin Ter; 1990 May; 133(4):227-31. PubMed ID: 2142910
[TBL] [Abstract][Full Text] [Related]
25. An immunomodulating drug, thymopentin, in the treatment of progressive systemic sclerosis.
Giordano N; Biasi G; Taddeo A; Marcolongo R; Bertelletti D
Clin Rheumatol; 1989 Jun; 8(2):293-4. PubMed ID: 2667863
[No Abstract] [Full Text] [Related]
26. Thymopentin treatment in genital warts of long duration.
Fransen L; Anthoons J; Hoogewijs G; Bolla K
Cancer Detect Prev; 1988; 12(1-6):503-9. PubMed ID: 3052838
[TBL] [Abstract][Full Text] [Related]
27. [Thymopentin in the treatment of cutaneous melanoma].
Trevisan G; Agolzer A
G Ital Dermatol Venereol; 1989 May; 124(5):245-9. PubMed ID: 2695455
[TBL] [Abstract][Full Text] [Related]
28. [Thymopentin as adjuvant therapy in the hepatitis B vaccination of non- or hyporesponsive subjects].
Fuliano P; Fontana L; Bigolari M; Bovone U; Orengo G; Astengo F
Minerva Med; 1990 May; 81(5):407-13. PubMed ID: 2198499
[TBL] [Abstract][Full Text] [Related]
29. Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin.
Pozzilli P; Visalli N; Cavallo MG; Beales P; Negri M; Ghirlanda G; Papa V; Andreani D
Diabetes Res; 1987 Oct; 6(2):51-6. PubMed ID: 2962799
[TBL] [Abstract][Full Text] [Related]
30. Thymopentin treatment in AIDS and pre-AIDS patients.
Clumeck N; Cran S; Van de Perre P; Mascart-Lemone F; Duchateau J; Bolla K
Surv Immunol Res; 1985; 4 Suppl 1():58-62. PubMed ID: 3898293
[TBL] [Abstract][Full Text] [Related]
31. [Use of thymopentin in the treatment of post-radiation cystitis].
Martinoli F; Catania G; Bertana F; Caldera G
Minerva Urol Nefrol; 1988; 40(4):275-6. PubMed ID: 3075095
[No Abstract] [Full Text] [Related]
32. Immunomodulation in infection caused by human immunodeficiency virus.
Phair JP
J Lab Clin Med; 1989 Feb; 113(2):135-6. PubMed ID: 2644386
[No Abstract] [Full Text] [Related]
33. Thymopentin in the treatment of juvenile chronic arthritis.
Bardare M; Corona F; Ogliari MT; Cohen E
Clin Exp Rheumatol; 1990; 8(1):89-93. PubMed ID: 1971780
[TBL] [Abstract][Full Text] [Related]
34. [The protective action of thymopentin on stress damage to the stomach].
Deviatkina TA; Tarasenko LM; Klusha VE; Tsebrzhinskiĭ OI; Mutsenietse RK
Biull Eksp Biol Med; 1989 Jun; 107(6):673-5. PubMed ID: 2676006
[TBL] [Abstract][Full Text] [Related]
35. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
[No Abstract] [Full Text] [Related]
36. Thymopentin in the treatment of severe alopecia areata.
Tosti A; Manuzzi P; Gasponi A
Dermatologica; 1988; 177(3):170-4. PubMed ID: 3049174
[TBL] [Abstract][Full Text] [Related]
37. Thymopentin treatment in a patient with pluriorificial pyoderma vegetans.
Simon M; Djawari D; Horstein OP; Bolla K
Surv Immunol Res; 1985; 4 Suppl 1():125-8. PubMed ID: 3898284
[TBL] [Abstract][Full Text] [Related]
38. Rationale for thymopentin as therapeutic agent in rheumatoid arthritis.
Franchimont P; Bolla K
Surv Immunol Res; 1985; 4 Suppl 1():70-5. PubMed ID: 3898295
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and tolerability of thymopoietin in patients at risk of infection].
Recenti Prog Med; 1987; 78(7-8):358-64. PubMed ID: 3321257
[No Abstract] [Full Text] [Related]
40. Immunomodulation and Sézary syndrome: experience with thymopentin (TP-5).
Bernengo MG; Doveil GC; Meregalli M; Appino A; Massobrio R
Br J Dermatol; 1988 Aug; 119(2):207-21. PubMed ID: 3139021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
